A compound is described. In particular, a non-steroidal sulphamate compound is described. The compound is suitable for use as an inhibitor of oestrone sulphatase. The compound is of general Formula (A), ##STR1## wherein R.sub.1 -R.sub.6 are independently selected from H, halo, hydroxy, sulphamate, alkyl and substituted variants or salts thereof, but wherein at least one of R.sub.1 -R.sub.6 is a sulphamate group; and wherein X is any one of S, NH, a substituted N, CH.sub.2, or a substituted C.
RELATED APPLICATIONS
This application is a continuation-in-part of allowed U.S. application Ser. No. 09/238,345 Jan. 27, 1999 now U.S. Pat. No. 6,187,766, which was a division of U.S. application Ser. No. 09/111,927, filed Jul. 8, 1998, now U.S. Pat. No. 6,011,024, which in turn was a continuation-in-part of inter alia PCT patent application number PCT/GB97/00444, filed Feb. 17, 1997, designating the U.S., and claiming priority from United Kingdom patent application 9603325.3, filed Feb. 16, 1996. PCT/GB97/00444 was published as WO 97/30041 on Aug. 21, 1997. This application is also a continuation-in-part of allowed application Ser. No 09/125,25, filed Aug. 14, 1998 now U.S. Pat. No. 6,239,169, as the National Phase (35 USC 371) of PCT/GB97/00444, Feb. 17, 1997, designating the U.S., published as WO 97/30041 on Aug. 21, 1997, and claiming priority from United Kingdom patent application 9603325.3, filed Feb. 16, 1996. Each of these applications and patents and each document cited or referenced in each of these applications and patents, including during any prosecution ("application cited documents"), and each document cited or referenced in each of the application cited documents, are hereby incorporated herein by reference. In addition, each document cited in this text ("herein cited documents") and each document cited or referenced in each of the herein cited documents, are hereby incorporated herein by reference.
